Cationic Steroidal Antimicrobial Salt Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clinical use of antimicrobial peptides is hindered by high production costs, susceptibility to proteases, and deactivation by lung mucosa components, necessitating the development of non-peptide mimics that maintain broad-spectrum antibacterial activity while being more stable and cost-effective.
Innovation Solution
Development of 1,5-naphthalenedisulfonic acid addition salts of cationic steroidal antimicrobials (CSAs), which are synthesized into solid, crystalline, or flowable forms, offering improved stability and pharmaceutical administerability through specific processes involving solvent dilution, acid addition, and temperature cycling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial peptides are used for clinical treatment, then broad-spectrum antibacterial activity is achieved, but production cost increases and susceptibility to proteases occurs
Solution Approach 1:
The patent creates non-peptide mimic compounds (ceragenins) that copy the essential amphiphilic morphology and cationic charge distribution of natural antimicrobial peptides. By using small molecule steroidal or non-steroidal structures with hydrophobic faces and cationic faces, the invention reproduces the antibacterial mechanism without using peptide bonds, thereby eliminating protease susceptibility and reducing production costs through simpler synthesis routes.
Solution Approach 2:
The patent modifies the chemical structure parameters by replacing peptide backbones with small molecule structures containing hydrophobic and cationic regions. This structural parameter change maintains the amphiphilic morphology necessary for membrane disruption while improving stability against enzymatic degradation and simplifying manufacturing processes.
2Reliability
If antimicrobial peptides are used, then antibacterial activity is achieved, but susceptibility to proteolytic degradation occurs
Solution Approach 1:
The patent creates non-peptide mimic compounds (ceragenins) that copy the essential amphiphilic morphology and cationic charge distribution of natural antimicrobial peptides. By using small molecule steroidal or non-steroidal structures with hydrophobic faces and cationic faces, the invention reproduces the antibacterial mechanism without using peptide bonds, thereby eliminating protease susceptibility and reducing production costs through simpler synthesis routes.
Solution Approach 2:
The patent employs small molecule structures that are inherently more stable than peptides against enzymatic degradation. These simplified molecular structures do not contain peptide bonds that proteases can cleave, effectively making them resistant to biological degradation without requiring complex stabilization strategies.
3Ease of manufacture
If non-peptide mimics are developed, then production cost decreases and protease stability increases, but water solubility and charge density control becomes challenging
Solution Approach 1:
The patent modifies the chemical structure parameters by replacing peptide backbones with small molecule structures containing hydrophobic and cationic regions. This structural parameter change maintains the amphiphilic morphology necessary for membrane disruption while improving stability against enzymatic degradation and simplifying manufacturing processes.
Solution Approach 2:
The patent applies local quality by creating distinct hydrophobic faces and cationic faces on the molecular structure. This spatial separation of properties allows the molecule to interact with bacterial membranes through hydrophobic insertion while the cationic face provides electrostatic attraction to negatively charged membrane components, enabling controlled solubility and membrane targeting.
4Reliability
If CSA salts are synthesized through traditional methods, then antimicrobial activity is achieved, but manufacturing complexity and storage stability issues occur
Solution Approach 1:
The patent employs preliminary action by pre-forming the free base form of the ceragenin compound through streamlined synthesis, then performing a simple salt formation step with appropriate acids to generate the final stable product. This two-stage approach with predetermined intermediates simplifies manufacturing and ensures consistent product quality.
Solution Approach 2:
The patent utilizes phase transitions by controlling the formation of crystalline salt forms from solution. By selecting appropriate acids and solvents, the ceragenin compounds form stable crystalline salts with improved storage stability and defined physical properties, facilitating standardized manufacturing and quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CSA salts exhibit comparable or enhanced antimicrobial activity, stability, and pharmaceutical properties, such as solubility and storage stability, simplifying synthesis and manufacturing compared to existing methods.
Implementation Method 1
diluting the free base of a CSA with a solvent; adding at least one equivalent of an acid to the diluted CSA in solvent
Implementation Method 2
precipitating or temperature cycling the reaction mixture; isolating a CSA salt
Implementation Method 3
temperature cycling the reaction mixture; The temperature cycling may be conducted for at least about 48 hours
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
Disclosed herein are acid addition salts of cationic steroidal antimicrobials ("CSAs" or "ceragenins") and methods of making the same. Particularly advantageous salt forms are identified, such as 1,5-naphthalenedisulfonic acid addition salts and sulfate addition salts. The acid addition salts may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Embodiments include formulations and methods of administering acid addition salts of CSAs.